SecBot SecBot
8-K ·Filed Sep 2, 2026

PASG

Passage BIO, Inc.
BULLISH
Impact 8/10
Horizonweeks Processed2mo ago SEC0001140361-26-035515
Killer combo: Material agreement + unregistered equity (likely PIPE/convertible)
Actionable Insight ▲ Bullish

This is a transformative reverse merger that effectively replaces Passage Bio with Remix Therapeutics. Traders should view this as a new entity with a different pipeline and management. The key catalyst is the successful closing of the merger and the concurrent PIPE, which provides the combined company with a substantial cash runway. Monitor the stockholder votes and regulatory approvals for the merger.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+20
Entry
$4.75
T+0 close · Sep 2, 2026 · via day close
Latest settled
−13.26%
T+20 · $4.12 · next T+60 in 13d
Vs SPY
−12.08%
α at T+20
Latest observation
+8.06%
T+50 · FF3 residual α
  1. T+0 · Sep 3 $4.75entry
  2. T+1 · 2mo ago −2.11%α −1.72% · $4.65
  3. T+5 · 2mo ago +5.26%α +6.41% · $5.00
  4. T+20 · 7w ago −13.26%α −12.08% · $4.12
  5. T+51 · todayOpen
  6. T+60 · in 13d Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Passage Bio (PASG) is acquiring Remix Therapeutics in a reverse-merger transaction valued at $226M for Remix's equity, with a concurrent $99.9M PIPE financing. The combined company will operate under the Remix name and pipeline, with Passage's existing assets (Legacy Assets) being divested and their proceeds distributed to Passage's pre-merger shareholders via Contingent Value Rights (CVRs). This is a transformative event that effectively replaces Passage's business with Remix's, making it a new entity for investors.

Key Financial Metrics

Deal Value
$226.0M
Deal Type
merger
Offering Size
$99.9M

Key Facts

  • Passage Bio is acquiring Remix Therapeutics via a two-step merger, with Remix valued at $226M in equity.
  • A concurrent PIPE financing of at least $99.9M is being raised to fund the combined company.
  • Passage's existing assets (Legacy Assets) will be sold, with proceeds distributed to pre-merger Passage shareholders through CVRs.
  • The combined company will be named Remix Therapeutics, Inc., and Passage's current management will be replaced by Remix's team.
  • The transaction requires approval from both Passage and Remix stockholders, with a target closing by December 24, 2026.

Financial Impact

Remix equity valued at $226M; concurrent PIPE of at least $99.9M; Passage equity valued at $20M.

revenueepsdilution

Risk Factors

  • The merger may fail to close if stockholder votes or regulatory approvals are not obtained.
  • The Legacy Asset Disposition may not be completed, or the CVRs may pay out zero.
  • The combined company's pipeline (Remix's) is still pre-commercial and carries clinical and regulatory risk.
  • The concurrent PIPE may not close, leaving the combined company undercapitalized.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
67% bullish (9 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001140361-26-035515
Document: ef20081513_ex10-6.htm0001140361-26-035515
Document: ef20081513_ex10-4.htm0001140361-26-035515

Track record

15 reports on PASG

Performance horizon

2 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +22.24% at T+60 after the May 27, 2026 report. 3 of 6 went positive at some point.

Filters
  1. Nov 6, 202610d ago 8-K Neutral 5/10 Entry $3.98 Now $4.13 +3.90% settles Dec 7
  2. Oct 13, 20265w ago EFFECT Neutral 3/10 Entry $3.64 to $3.78 Now $4.13 +13.46% ▲ +3.85% +7.46% vs SPY
  3. Oct 8, 20265w ago S-4/A Bearish 6/10 Entry $3.69 to $3.98 Now $4.13 −11.92% ▼ −7.72% −13.28% vs SPY
  4. Oct 5, 20266w ago S-4/A Neutral 5/10 Entry $4.08 to $3.41 Now $4.13 +1.23% ▼ −16.47% −13.56% vs SPY
  5. Sep 21, 20268w ago S-4/A Neutral 5/10 Entry $4.95 to $3.60 Now $4.13 −16.57% ▼ −27.27% −26.71% vs SPY
  6. Sep 2, 202610w ago S-4/A / 425 Bearish 8/10 Entry $4.75 to $4.12 Now $4.13 +13.05% ▲ +13.26% +12.08% vs SPY
  7. Sep 2, 202610w ago 8-K Bullish 8/10 Viewing Entry $4.75 to $4.12 Now $4.13 −13.05% ▼ −13.26% −12.08% vs SPY
  8. Jun 24, 202620w ago 425 Bearish 7/10 Entry $4.33 to $4.90 Now $4.13 +4.62% ▼ −13.16% −12.64% vs SPY
  9. Jun 24, 202620w ago 425 Bearish 7/10 Entry $4.33 to $4.90 Now $4.13 +4.62% ▼ −13.16% −12.64% vs SPY
  10. Jun 24, 202620w ago 8-K Bearish 7/10 Entry $4.33 to $4.90 Now $4.13 +4.62% ▼ −13.16% −12.64% vs SPY
Showing 10 of 15

US Market Status

Market Closed · Opens in 6h 36m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Sep 3, 2026